FACIT s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
by Ron Johnson for TRNTO Posted: January 29, 2021
Providence Therapeutics, based in Toronto and Calgary, is a Canadian biotechnology company founded in 2015 to work in cancer research. Early research work was done with JLABS in Toronto’s MaRS Discovery District as well as the Sunnybrook Research Institute. When COVID-19 hit, the company pivoted and quickly designed a vaccine. Without any domestic facilities, Canada is having to rely on foreign companies for its current vaccine requirements. And we are seeing what’s happened with that strategy on display this week. But that is changing. Now, Providence has invested in a Calgary manufacturing facility and is gearing up to answer the call. Human trials are underway, and the company could start distributing vaccines this year if the federal government commits to an order.
Posted on 288
Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s
paxalisib and Kintara’s
VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that tests multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
Kazia’s
paxalisib and Kintara’s
VAL-083 are entering the GBM AGILE trial, which initially opened in July 2019 and has screened over 370 patients to date.